In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...
Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia ...
Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...
News-Medical.Net on MSN
Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...
9don MSN
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...
Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.
For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback